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Abstract
Background: Traditional Chinese medicine (TCM) has been widely used in treating various diseases in eastern Asia
for several thousand years, and is becoming increasingly popular in western countries. Gubentongluo (GBTL)
decoction, as a classic TCM formula, is commonly applied to treat IgA Nephropathy (IgAN) in China. To date,
however, the pharmacological/molecular mechanisms of GBTL have not been fully elucidated.
Method: In the present study, we used a system biological approach to explore these mechanisms acting on IgAN.
Results: First, we found 3876 potential target proteins for GBTL (based on TCMID) and 25 known IgAN associated
biomarkers (based on the OMIM or IPA database).16 of the latter biomarkers were direct targets of 6 of the 9 herbs
in GBTL, suggesting that these components play a vital role in treating IgAN. Second, we showed that these 6
herbs mainly regulate the immune system and renin-angiotensin system, imbalance in which is the main factor
leading to IgAN. Importantly, HUANG QI links with 14 biomarkers, indicating that it is the most important herb in
GBTL for treating IgAN. Also, relationships of other herbs with IgAN were explored. Third, we demonstrated that the
remaining 9 IgAN associated proteins are responses to biological processes, such as antigen processing, protein
ubiquitination and cell cycle regulation, which are crucial for IgAN development. Finally, we found that GBTL could
induce a significant increase in the levels of two target gene: TNF and NOS2.
Conclusions: Further studies are called to develop/modify the formula of GBTL, in order to enhance its effect on
IgAN.
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Background
Traditional Chinese medicine (TCM), as a system of
ancient medical practice, has been widely used in treat-
ing various diseases in Eastern Asia for many years.
TCM continues to play a critical role in maintaining
health for the peoples of China, and is growing in popu-
larity in Western countries [1]. Notably, modern medical
researchers have adopted ideas from TCM, using combi-
nations of drugs to treat complex diseases such as can-
cer and diabetes.
In last decades, researchers have made great efforts to
investigate TCMs and to analyze their components. To
date, numerous bioactive ingredients of TCMs have been
isolated and identified [2]. This has furthermore led to
the discovery of a variety of single compound-based
therapeutics in TCM, such as the anti-cancer compound
salvicine [3]. Indeed, these data/database can provide
important hints/information for further biological sys-
tematic studies, however, TCM protocols should take
a more holistic method; the TCMs always works as
the result of synergistic interactions by multiple
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ingredients [4]. Thus, to truly investigate TCMs, bio-
logical systematic methods should be applied, all the
ingredients of herbs or formulae in TCM should be
taken into consideration simultaneously [e.g. 5–7].
Currently, the most applied strategy in drug discovery
is ‘one gene–one drug–one disease’ paradigm, involving
the screening of potential compounds for individual
disease-causing targets. In this case, the drug’s efficacy is
often impaired, because the robustness of the protein
interactions in the treated objectives was ignored. There-
fore, the biological systems-oriented approaches, such as
combinations of effective drugs with multiple targets,
were called in drug discovery [8]. The TCM presents a
perfect example, as it treats diseases in a holistic way. In
the formulae of TCM, over hundreds compounds were
always be treated simultaneously to rebalance the organ-
ism. Therefore, TCM formulae with multi-components/
targets should be analyzed by the same strategy as com-
bination therapies of multi-component drugs.
IgA Nephropathy (IgAN), a primary glomerular disease,
is the most common type of Chronic Kidney Disease
(CKD) which is a common condition affecting up to 11 %
of the population. This disease is now recognized to ele-
vate the risk of cardiovascular disease as well as kidney
failure and other complications [e.g. 9, 10]. It is a leading
cause of end-stage kidney disease in China [11]. Effective
control of proteinuria may be a key strategy for treating
CKD [reviewed in 12]. Reninangiotensin-aldosterone sys-
tem blockers, glucocorticoids, and immunosuppressants
have often been used for primary glomerular diseases. Im-
munosuppressive therapies have usually been applied to
treat patients with heavy proteinuria, but are not entirely
suitable for patients with non–nephrotic-range proteinuria
[13]. Moreover, treatments with glucocorticoids and
immune-suppressants are usually long term, which can re-
sult in severe adverse effects and increase the risk of re-
bound [e.g. 13, 14]. TCM has promising effects on the
control of proteinuria, protection of kidney function, and
improvement in patients’ clinical symptoms [e.g. 15, 16].
For example, Abelmoschus manihot, a traditional Chinese
herb, has increasingly been used to treat a wide range of
types of CKD, such as immunoglobulin A (IgA), nephrop-
athy (IgAN) and diabetic nephropathy [e.g. 17, 18]. Clin-
ical studies have proven that A. manihot can reduce
proteinuria and thus protect kidney function [e.g. 19].
However, TCM formulae are multi-component and multi-
target agents, and it is therefore necessary to investigate
the combination therapy of multi-component drugs.
Gubentongluo (GBTL) decoction, a classic TCM for-
mula from Chinese medical sage Zhang Zhongjing, is
prepared from a basic formula of nine herbs, including
Rhizoma imperatae (BAI MAO GEN), Ramulus euonymi
(GUI JIAN YU), Yerbadetajo herb (HAN LIAN CAO),
Fructus ligustri lucidi (NU ZHEN ZI), Astragali radix
(HUANG QI), Semen persicae (TAO REN), Rumex
madaio (YANG TI GEN), Herba lycopi (ZE LAN YE)
and Radix salvia miltiorrhizae (DAN SENG). It is widely
used in China in accordance with the China
Pharmacopoeia standard of quality control. In TCM the-
ory, the multiple agents contained in a single formula
must work synergistically. With regard to GBTL, Rhi-
zoma imperatae is the primary herbs and is believed to
be a very effective antioxidant, whereas Ramulus euo-
nymi acts primarily as an anti-inflammatory. For the
most part, however, it’s the pharmacological/molecular
mechanisms of GBTL have not yet been fully elucidated.
In this study, we have developed a comprehensive sys-
tematic approach for understanding the pharmacological
mechanisms of GBTL acting on IgAN; an overview of
our approach is shown in Additional file 1: Figure S1.
Three steps were taken to achieve this objective: (1) pre-
diction of potential targets for GBTL; (2) collection of
IgAN associated molecules and construction of an IgAN
associated regulation network; (3) study of the relation-
ships of GBTL potential targets with the network and
corresponding signal pathways and (4) examine whether
the treatment of GBTL induces changes in potential tar-
gets expression. This procedure would enhance our un-
derstanding of the pharmacological mechanisms of
GBTL and its limitations.
Methods
Description of herbs in GBTL and prediction of potential
targets for GBTL and selection of IgAN-associated genes
and proteins
The description of herbs in GBTL was obtained from the
Traditional Chinese Medicine Integrated Database
[TCMID, 5], which is the most commonly used noncom-
mercial TCM database worldwide. In total, we collected in-
formation on nine herbs, i.e., Rhizoma imperatae, Ramulus
euonymi, Yerbadetajo herb, Fructus ligustri lucidi, Astragali
radix, Semen persicae, Rumex madaio, Herba lycopi and
Radix salvia miltiorrhizae. Putative targets of the active in-
gredients (compounds) of each herb were identified poten-
tial in the TCMID, a comprehensive collection of herb
ingredients’ targets based on articles published in both
English and Chinese. The IgAN- associated genes and pro-
teins were collected from two IgAN related databases, in-
cluding OMIM (http://www.ncbi.nlm.nih.gov/omim [20]
and IPA [21] (www.ingenuity.com).
Protein-protein interaction (PPI) data
Protein-protein interaction (PPI) data were extracted
from the STRING database version 9.1 (http://string-
db.org/; [22]. Confidence scores for each pair of interact-
ing proteins were calculated by combining probabilities
from the different evidence channels, and correcting for
the probability of observing random interactions. As
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these proteins don’t interact with each other directly, an
integrated auto expanding algorithm was used to seek
potential linking proteins between them. Among these
expanded links, proteins that occur along the shortest
path between the indirectly interacting pairs were kept
to construct a fully connected network model.
Pharmaceutical network construction and analysis
The PPIs between IgAN associated proteins were used
to construct an IgAN associated regulation network.
First, using Venn diagrams (http://www.omicsbean.-
com:88; Venn 1880), we identified: 1) overlapping pro-
teins between the potential targets of each ingredient in
GBTL and IgAN associated proteins (Group 1), 2) po-
tential targets of each herb in GBTL which were not
covered by the IgAN associated protein set (Group 2)
and 3) IgAN associated proteins not included among the
potential targets of each ingredient in GBTL (Group 3).
Then, we explored the potential molecular mechanisms
of GBTL acting on IgAN, by investigating the overlap-
ping proteins between the potential targets of each herb
in GBTL and IgAN- associated proteins. Finally, we tried
to reveal the limitations of treating IgAN with GBTL
alone, by studying the candidate proteins (of GBTL)
which were not covered by the IgAN-associated protein
set.
Furthermore, the herbs of GBTL, their potential tar-
gets, and the IgAN associated proteins were respectively
used to construct an herb-potential target network, po-
tential target PPI, IgAN associated protein PPI and
herb-potential target-candidate IgAN target network.
Cytoscape Version 3.1 [23] was applied to visualize the
networks.
Gene Ontology (GO) and pathway enrichment analysis for
IgAN associated proteins and potential targets of GBTL
We used Database for Annotation, Visualization and
Integrated Discovery (DAVID, version 6.7; [24] for GO
enrichment analysis. The enrichment score was calcu-
lated using hypergeometric enrichment algorithms [25].
The EASE (Expression Analysis Systemic Explorer) score
was set to the default value [26]. We also performed path-
way enrichment analysis using pathway data obtained
from the FTP service of KEGG (Kyoto Encyclopedia of
Genes and Genomes, http://www.genome.jp/kegg/; [27].
P-values of the KEGG pathway were calculated using the
Fisher exact test. Pathways with P-value <0.05 were taken
as significantly enriched.
Animal experiments
To examine whether the treatment of GBTL induces
changes in potential targets expression, 7 male Hae-
mophilus parainfluenzae antigens (OMHP) induced
IgAN C3H/HeN mice were obtained from Shanghai Key
Laboratory of Traditional Chinese Clinical Medicine
(shanghai, china), and then randomly divided into two
groups: the model group (n = 3) and GBTL-treated group
(n = 4). The mice in GBTL-treated group were adminis-
trated with GBTL by intragastric at a dose of 10 g/kg
bodyweight once a day for 3 days.
Quantitative RT-PCR
After 3 days, all mice were killed and the kidneys re-
moved from mice immediately were placed in liquid ni-
trogen. The kidneys were grinded into powder with
pestle by adding liquid nitrogen. Total RNA was isolated
from the powder of kidney (50 mg) using Trizol (Aidlab,
China) by following the manufacturer’s instructions.
Synthesis of single-stranded cDNA from 5 ìg of RNA
was performed according to the “TUREscript 1st strand
cDNA Synthesis Kit” from Aidlab (China), then, the
mRNA was reverse transcribed into cDNA. Quantitative
RT-PCR was performed using the QuantiTect SYBR
Green PCR Mix (Qiagen) in a Roche LightCycler 480 II.
The following primer pairs were used in this study to
detect specific mRNAs, blinded to the treatment status
of each sample: GAPDH: forward primer: GAG TCA
ACG GAT TTG GTC GT; reverse primer: TTG ATT
TTG GAG GGA TCT CG; TNF: forward primer:
CCTGTAGCCCACGTCGTAG; reverse primer:
GGGAGTAGACAAGGTACAACCC; NOS2: forward
primer: AACCCCTTGTGCTGTTCTCAG; reverse pri-
mer: TGTGGCCTTGTGGTGAAGAG. Reaction condi-
tions were set to 3 min at 95 °C (first segment, one
cycle), 15 s at 95 °C and 60 s at Tm of a specific primer
pair (second segment, 40 cycles) followed by 90 s at 90 °C,
60 °C for 3 min and 10s at 94 °C(Melting segment, one
cycle) using Funglyn FTC-3000 (Funglyn Biotech). Rela-
tive gene expression was defined as a ratio of target gene
expression versus â-actin gene expressionQuantification
and comparisons of gene expression levels were per-
formed using the −ÄÄCt method, and statistical analyses
of differences between control and model and treatment
group.
Results
Shared protein targets involved mainly in immune system
process and regulation of renin-angiotensin system
The 9 herbs of GBTL yielded 237 components and fur-
ther resulted in 3867 potential proteins (list not shown),
based on the TCMID database, whereas 25 IgAN associ-
ated proteins were detected from the OMIM or IPA
database. Of the latter, 16 IgAN associated proteins, in-
cluding ACE, TP53, JUN, TNF etc, were also determined
to be the potential targets for GBTL (Fig. 1a; proteins
listed in Table 1). It’s known that IgAN is associated with
high levels of mononuclear leukocyte infiltration into
the kidney [28], gene ontology enrichment of these
Shen et al. BMC Complementary and Alternative Medicine  (2016) 16:312 Page 3 of 10
proteins indicates that the leukocyte proliferation is the
most relevant, with IMPDH1,IMPDH2, ACE, and TP53
involved. These genes were also proven to be associated
with regulation of immune system process [29, 30]. More-
over, several important biological processes were found to
be related to IgAN, such as angiotensin maturation, regu-
lation of renal output by angiotensin and response to salt
stress (Fig. 1b). These processes were linked to renin-
angiotensin system which was the most used target sys-
tems for IgAN therapies [31], indicating that the pharma-
ceutical effects of the GBTL in treating IgAN might
mainly through regulation of the leukocyte level and of
the renin-angiotensin system, which could then regulate
blood pressure and water balance in the IgAN patients.
Functional analysis reveals GBTL could regulate innate
immune response and inflammatory responses
Of 3867 potential targets of GBTL, 16 is overlapped with
IgAN associated proteins, other 3851 proteins that are
not directly linked to the IgAN (Fig. 1a). Figure 1c listed
top 50 related biological processes of three groups of
proteins (see methods), respectively. Processes, such as
regulation of kidney development, cytokine production,
renal output by angiotensin and hypoxia, are related to
proteins in Group 1, as the core regulation mechanism
to explain the effectiveness of GTBL. However, regula-
tion of ERK1/2 cascade, chemotaxis, transmembrane
transport, TLR signaling, innate immune response and
inflammatory response are related to targets in Group 2.
Indeed, Dys-regulated innate immune response and in-
flammatory response are likely causing failure of muco-
sal antigen elimination and IgA synthesis, and TLRs are
relevant mediators of mucosal immunity [32]. Overall,
GBTL could be able to regulate mucosal immunity and
inflammatory responses.
In Group 3, we found that the 9 non-overlapping IgAN
associated proteins play important roles in cell cycle regula-
tion, protein ubiquitination and presentation of exogenous
peptide antigen via MHC class I (Table 2). These pathways
are all linked with the proteasome machinery [33].
Core regulation network suggests HUANG QI is the key
herb in GBTL
Based on PPI analysis, we found that 6 (i.e. GUI JIAN
YU, HUANG QI, NU ZHEN ZI, ZE LAN YE, TAO
REN, YANG TI GEN, DAN SHEN) out of 9 ingredients
of GBTL acted on 16 associated proteins of IgAN (Fig. 2).
Then, focus on the 16 covered biomarkers of IgAN, we
have constructed a core regulation network. In this
network, these 16 proteins linked different processes, in-
cluding leukocyte proliferation, T cell receptor signaling
pathway, renin-anglotensin system, response to hypoxia,
fat digestion and absorption and immune systems
process. HUANG QI is the most important herb in
Fig. 1 a Distribution of potential targets Gubentongluo decoction proteins and IgA Nephropathy - associated proteins, b Biological process
enrichment result for 16 candidate proteins and c Heatmap of top 50 biological processes enriched in three groups. The color legend indicates
association with the group, red means most relevant whereas the green indicates irrelevant
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GBTL, as it contributes as a hub, connecting 14 target
proteins. Based on the network model, HUANG QI
could regulate leukocyte proliferation via IMPDH, ACE
and TP53; the ion homeostasis via AGT and VDR, and
hypoxia via ACTN4, MDM2 and NOS2. Indeed, it was
showed that IgAN was associated with coupled up-
regulation of iNOS and P53 that might linked with
apoptotic activity of renal cells [34], suggesting that the
hypoxia and P53 signaling are potential target pathway
of GBTL. Moreover, these processes, which HUANG QI
could be involved in, are linked with immune system
processes with IgAN [35]. Therefore, the GBTL could
regulate the immune systems and then act on IgAN.
The KEGG pathway enrichment analysis showed that
these 14 proteins (i.e. the HUANG QI targeted in) were
annotated in 20 different KEGG pathways, of which the
most important pathway is the renin-angiotensin sys-
tem. Moreover, the cell cycle and the Wnt signaling
pathway are also highly associated. These pathways
have been actively studied for the treatment of IgAN in
recent years [36].
Contribution of other herbs in GBTL
NU ZHEN ZI acts as the second hub in the network
(Fig. 2), it could target both AGT (Angiotensinogen, an
essential component of the renin-angiotensin system)
and TP53. AGT is a potent regulator of blood pressure,
body fluid and electrolyte homeostasis [37–39], whereas
TP53 is key player in apoptotic activity in the pathogen-
esis of progressive IgAN [34]. This herb could also target
JUN, a transcriptional factor, actives expression of IL-2,
IFN and TNF in the T cell receptor signaling pathway,
which further link to iNOS via HIF-1 signaling pathway.
DAN SHEN could target 6 proteins, 5 (JUN, TP53,
TNF, NOS2, HAVCR1) of them are shared with
HUANG QI or NU ZHEN ZI, suggesting it could have
similar pharmaceutical effects as HUANG QI or NU
ZHEN ZI. Another target is DGAT1, Diacylglycerol O-
acyltransferase, a key metabolic enzyme converts diacyl-
glycerol and fatty acyl CoA in the fat digestion and
absorption pathway. This target is shared with YANG TI
GEN, which targets not only DGAT1, but also DGAT2
(a homolog protein of DGAT1). Therefore, both the
Table 1 The list of 25 IgAN associated proteins
Uniprotein ID Symbol Name Presence in GBTL
O43707 ACTN4 actinin, alpha 4 Yes
O75907 DGAT1 diacylglycerol O-acyltransferase homolog 1 Yes
P00797 REN Renin Yes
P01019 AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) Yes
P01375 TNF tumor necrosis factor (TNF superfamily, member 2) Yes
P04637 TP53 tumor protein p53 Yes
P05412 JUN jun oncogene Yes
P11473 VDR vitamin D (1,25- dihydroxyvitamin D3) receptor Yes
P12268 IMPDH2 IMP (inosine monophosphate) dehydrogenase 2 Yes
P12821 ACE angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 Yes
P20839 IMPDH1 IMP (inosine monophosphate) dehydrogenase 1 Yes
P35228 NOS2 nitric oxide synthase 2, inducible Yes
P49721 PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 Yes
Q00987 MDM2 Mdm2 p53 binding protein homolog (mouse) Yes
Q96D42 HAVCR1 hepatitis A virus cellular receptor 1 Yes
Q96PD7 DGAT2 diacylglycerol O-acyltransferase homolog 2 Yes
O00151 PDLIM1 PDZ and LIM domain 1 No
P11836 MS4A1 membrane-spanning 4-domains, subfamily A, member 1 No
P20618 PSMB1 proteasome (prosome, macropain) subunit, beta type, 1 No
P28074 PSMB5 proteasome (prosome, macropain) subunit, beta type, 5 No
P35612 ADD2 adducin 2 (beta) No
P43405 SYK spleen tyrosine kinase No
Q13200 PSMD2 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 No
Q14005 IL16 interleukin 16 (lymphocyte chemoattractant factor) No
Q99460 PSMD1 proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 No
GBTL indicated the Traditional Chinese Medicine Gubentongluo decoction
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DAN SHEN and YANG TI GEN are responsible for syn-
thesis of triglycerides. Indeed, increased level of triglyc-
erides is a known nephritic syndrom in IgAN [40], thus,
the GBTL may have potential effect on regulating the
triglycerides level of IgAN patients.
The other two herbs, GUI JIAN YU and TAO REN,
target AGT, REN and TNF, NOS2. The protein-protein
interactions analysis showed that these proteins are
interacted. AGT and REN are key roles in renin-
angiotensin system, and NOS2 is induced by hypoxia.
It’s known that the renin-angiotensin system could lead
to hypoxia via induced oxidative stress, which causes
directly endothelial cell damage [41]. Also, Hypoxia acti-
vates macrophage to express NOS2 and produce NO to
lead to cell apoptosis [42]. The interacting network of
AGT, REN, TNF andNOS2 could be a reasonable ex-
planation that use combination of GUI JIAN YU and
TAO REN could act on the upstream RAS system and
downstream renal hypoxia simultaneously to provide
better therapeutic effect on IgAN.
EBV pathway is one of potential affected pathways of GBTL
Mesangial deposition of immunoglobulin A (IgA) is a
main character of IgAN, and the up-regulated IgA level
Table 2 Biological processes of nine IgA Nephropathy associated proteins, which were not covered by Gubentongluo decoction
GO ID Term P value P value FDR Gene
GO:0006977 DNA damage response, signal transduction by p53









GO:0051436 negative regulation of ubiquitin-protein ligase activity

















GO:0016032 viral process 3.71E-07 4.59E-03 SYK
IL16
GO:0002376 immune system process 7.59E-06 9.39E-02 ADD2
SYK
MS4A1
GO:0043306 positive regulation of mast cell degranulation 1.45E-05 1.79E-01 SYK
MS4A1
GO:0051171 regulation of nitrogen compound metabolic process 4.45E-03 1.00E + 00 PDLIM1
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is positively associated with IgAN [43]. The Epstein-Barr
virus (EBV) is a ubiquitous human herpes virus that is
related with oncogenesis. A previous study has shown
that EBV could up-regulate IgA in IgAN [44]. The EBV
pathway was found to be the third most significantly
associated pathway (P = 2e-0.5) with IgAN. Moreover, as
shown in Fig. 3, the EBV pathway is regulated by 6 IgAN
associated proteins (JUN, MDM2, PSMD1, PSMD2, SYK
and TP53), 4 of them (JUN, MDM2, PSMB2 and TP53)
are targeted by GBTL, suggesting that EBV pathway
Fig. 2 Core interaction network of components of Gubentongluo decoction on IgA Nephropathy. Triangle indicates the herbs, circle represent
proteins, green colored indicates potential target, white colored indicates extended linking proteins, and yellow colored rectangle indicates
related biological process. Solid line between two circles represents protein-protein interaction, the width of the line indicates confident score of
the interaction; whereas the dashed line linked proteins to related processes
Fig. 3 The pathway of Epstein-Barr virus infection affecting by the IgA Nephropathy associated proteins. The red and blue indicated the proteins
covered by Gubentongluo decoction, whereas the yellow ones means uncovered in this formula of Traditional Chinese Medicine
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could be one of affected pathways in GBTL treatment.
Two IgAN associated proteins (PSMD1 and SYK) were
not covered by GBTL. SYK is known involved in down-
stream signaling of IgA1 stimulation, and serve as an
important regulator to reduce the synthesis of MCP-1,
IL-6,IL-8, and inhibit mesangial cell proliferation [45].
GBTL treatment induced a significant increase in the
levels of TNF and NOS2
Two hub proteins (TNF: T cell receptor signaling,
NOS2: response to hypoxia) for validation test were ap-
plied qRT-PCR with the kidney samples. GBTL treat-
ment induced a significant increase in the levels of TNF
(p = 0.046) and NOS2 (p = 0.018; Fig. 4).
Discussion
In the present study, by using a systematic biology
method, we investigated the molecular mechanisms of
GBTL on treating the IgAN. Moreover, by using animal
model, we found GBTL induced a significant increase in
the levels of two target genes: TNF and NOS2. This pro-
vide an example for understanding the multiple targets
of herbs in Traditional Chinese Medicine formulae and
their interaction in the context of a molecular network
[reviewed in 46]. Our work also indicated that a single
TCM formula could be applied to the treatment of a
given disease, since only parts of disease-based associ-
ated proteins were covered.
This work is the first study to show that the potential
targets of GBTL could cover 16 of the 25 proteins which
are believed to be associated with IgAN. This explains
why GBTL is most effective for IgAN [e.g. [47–49].
Moreover, 6 of the 9 herbs of GBTL were determined to
act on the 16 associated proteins of IgAN. HUANG QI
is the most important component in the network, as it
interacts with 14 IgAN associated proteins. Many previ-
ous studies have shown that HUANG QI can enhance
myocardial contractility, improve circulation, protect
myocardial cells and regulate immunity [e.g. 50, 51].
Our findings, in good agreement with a large number of
other studies, indicate that HUANG QI has anti-viral,
anti-inflammatory and immunoenhancing effects [e.g.
52–54]. Furthermore, by DGAT1and DGAT2, YANG DI
GEN participates in the regulation of renin synthesis,
which is associated with fat metabolism. In addition, NU
ZHEN ZI, TAO REN and HUANG QI can be involved
in T cell receptor signaling regulation though the TNF
and JUN pathways. Since GBTL combines these herbs, it
can provide an effective treatment to IgAN.
Out of 25 selected biomarkers of IgAN, 9 proteins were
not overlapped with the potential targets of GBTL. En-
richment analysis of these 9 proteins suggests that bio-
logical processes such as G1/S transition of mitotic cell
cycle, regulation of platelet activation, regulation of actin
filament are also related to IgAN pathogenesis, however,
GBTL may not able to regulate these processes, at least
not directly as can be seen from the data. It suggests that
this formula might have some shortcomings in the treat-
ment of IgAN and could be improved in the future.
Moreover, many studies have already suggested that
some of the herbs used in Chinese medicine can interact
with drugs, and can have serious side effects [e.g. 55,
56]. In this study, more than 3800 proteins were not as-
sociated with IgAN directly. Although we showed that
some of processes such as innate immune response and
inflammatory response should associated with IgAN ac-
cording to previous studies, processes such as synaptic
transmission and response to drug could be related to
potential side effects of GBTL. In contrast, the afore-
mentioned 9 IgAN associated proteins are involved in
several key biological processes, especially related to pro-
teasome machinery. Most importantly, we have shown
that in the pathway of the EBV, key genes/proteins
(PSMB1 and SYK) related to the proteasome and down-
stream IgA1 production, were not targeted by GBTL
directly.
Three herbs, BAI MAO GEN, ZE LAN YE and HAN
LIAN CAO, were not associated directly with the IgAN,
according to the current protein datasets. However, we
analyzed these herbs separately and revealed that Bai
Mao Gen is mainly associated with pathogenic E. Coli
infection, gap junction and phagosome, Ze Lan Ye regu-
late mainly galactose metabolism, whereas, Han Lian
Cao is related with NOD-like receptor signaling, TLR re-
ceptor signaling and TNF signaling (data not shown).
These pathways were believed to be correlated with
IgAN [e.g. 57–59], indicating that these herbs should
have additive or complementary effect together with
other herbs in GBTL.
Fig. 4 qRT-PCR analysis of relative expression level of TNF and NOS2
among three groups: Control: healthy mice, Model: OMHP induced
IgAN model and Treatment: 3 weeks treated with GBTL. Data were
normalized according to the β-actin expression level. * < 0.05
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Conclusions
In this study we have shown the molecular mechanism
of GBTL acting on IgAN. The GBTL potential protein-
IgAN associated protein interactions showed that 6
herbs in GBTL acted on 16 IgAN associated proteins,
mainly through the renin-angiotensin system, regulate
the leukocyte proliferation and hypoxia, which are re-
sponsible for epithelial cell damage and leukocyte infil-
tration. DAN SHEN and YANG TI GEN have potential
power to regulate the triglycerides level via DGAT1 and
DGAT2. This demonstrates the basic therapeutic mecha-
nisms of GBTL in treating IgAN. Our study also indi-
cated that GBTL could not cover all IgAN associated
biomarkers, such as Syk, a key mediator relevant to
IgA1 stimulation. Overall, our study was the first to ex-
plore the molecular network of GBTL acting on IgAN,
and further studies are called for to develop the formula
of GBTL and to enhance its effectiveness on IgAN.
Additional file
Additional file 1: Figure S1. Overview of data generation, processing
and analysis. (JPEG 118 kb)
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